American Tower on Pace for Largest Percent Decrease Since September 2023 — Data Talk
American Tower Corporation (AMT) is currently at $184.90, down $7.91 or 4.1%
--Would be lowest close since Nov. 13, 2023, when it closed at $183.62
--On pace for largest percent decrease since Sept. 21, 2023, when it fell 4.56%
--Currently down four of the past five days
--Down 6.42% month-to-date
--Down 14.35% year-to-date
--Down 39.1% from its all-time closing high of $303.62 on Sept. 8, 2021
--Down 12.48% from 52 weeks ago (April 12, 2023), when it closed at $211.26
--Down 15.5% from its 52-week closing high of $218.81 on Jan. 2, 2024
--Up 17.26% from its 52-week closing low of $157.68 on Oct. 4, 2023
--Traded as low as $183.05; lowest intraday level since Feb. 27, 2024, when it hit $181.16
--Down 5.06% at today's intraday low; largest intraday percent decrease since July 20, 2023, when it fell as much as 5.24%
All data as of 10:02:10 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 10, 2024 10:20 ET (14:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track